Changes in and Determinants of Quality of Life in Patients With Advanced Non-Small-Cell Lung Cancer Undergoing Initial Chemotherapy

Dai, Yu-Lee; Yang, Cheng‐Ta; Chen, Kanghua; Tang, Siew Tzuh

doi:10.1097/jnr.0000000000000148

Cited by 18 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the resilient-growth profile suggests that some individuals were not merely lacking significant distress but might thrive through the experience (Carver, 1998;O'Leary & Ickovics, 1995), thus contributing to better HRQoL over time. Participants with distressed profiles reported relatively poor HRQoL, which is consistent with results in prior studies indicating that elevated emotional distress could contribute to worse HRQoL for adult cancer patients (Tang et al, 2017) and childhood cancer survivors (Huang et al, 2017). Finally, the current study is novel in examining the HRQoL in a subgroup of individuals who endorsed elevated emotional distress and growth.…”

Section: Discussionsupporting

confidence: 86%

Profiles of emotional distress and growth among adolescents and young adults with cancer: A longitudinal study.

Chen¹,

Zebrack²,

Embry³

et al. 2020

Health Psychology

View full text Add to dashboard Cite

Objective: This study investigated profiles of emotional distress and growth in adolescents and young adults (AYAs) with cancer. Clinical, demographic, and psychosocial factors were examined for their potential to distinguish these profiles and predict health-related quality of life (HRQoL) of AYAs with cancer. Method: This was a multicenter, longitudinal study of AYAs diagnosed with cancer at 14 -39 years of age. Participants were assessed 3 times over 24 months following a baseline survey administered at diagnosis. Four profiles (resilient, resilient growth, distressed, distressed growth) were derived using published cutoff points on standardized measures of depression, anxiety, posttraumatic stress disorder, and posttraumatic growth. Mixed-effects models were used to examine profile correlates and the extent to which profiles were associated with HRQoL. Results: Among 179 participants at Time 1, the proportion of profiles ranged from 18.8% for the resilient profile to 30.4% for the distressed-growth profile. These proportions remained consistent over time. Factors that appeared to distinguish these profiles included work or school status, sex, race, age at diagnosis, treatment status, prognosis, and personality characteristics. When compared to AYAs with resilient-growth profiles, HRQoL was significantly worse for AYAs reporting distressed and distressed-growth profiles, controlling for demographic, clinical, and social characteristics. Conclusion: The current study found 4 patterns of psychological adjustment in AYAs with cancer. The resilient-growth profile was associated with better HRQoL, whereas distressed and distressed-growth profiles were associated with worse HRQoL.

show abstract

Section: Discussionsupporting

confidence: 86%

Profiles of emotional distress and growth among adolescents and young adults with cancer: A longitudinal study.

Chen¹,

Zebrack²,

Embry³

et al. 2020

Health Psychology

View full text Add to dashboard Cite

show abstract

“…Each interview lasted approximately 30 minutes (8) . 7 th edition tumor-node-metastasis (TNM) staging system were used (7) . Response and ECOG/Karnofsky performance scores assessment was performed after 2 nd -4 th cycles.…”

Section: Data Collectionmentioning

confidence: 99%

“…In patients with advanced lung cancer, clinicians should enhance their ability to notice patients' elevated risk of poor QoL during CT. They should also detect and manage the related physical symptoms and side effects, strengthen patients' social support and control the anxiety and depressive symptoms (7) .…”

Section: Introductionmentioning

confidence: 99%

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

Güvençli¹,

Yalnız²,

Kömürcüoğlu³

et al. 2021

Terh

View full text Add to dashboard Cite

Objective: The concept of quality of life (QoL) in lung cancer includes many physical, psychological and social components. We aimed to assess the effect of chemotherapy (CT) on QoL of lung cancer patients using QoL scales. Methods: Fifty inoperable lung cancer patients who were newly diagnosed and taken into a CT plan were included. Patients were followed in terms of responsiveness and toxicity. Turkish versions of the EORTC QLQ-C30 and LC13 scales were used before every cycles. Results: The average age was 60.1 years. There was no difference between QoL and age/income levels. The assessment of physical, social and occupational functions and overall health status of the male patients was better than female. Overall health status without comorbidity was better in the first cycle CT. Chemotherapy led to deterioration in social functions and economic status together with increase in neuropathy, constipation and hair loss. Patients with complete or partial response to treatment were observed to have better physical, occupational, emotional, cognitive and social functions, economic status and overall health; less fatigue, pain, shortness of breath, neuropathy and better appetite. Toxicities were found to affect the QLQ C30 and LC13 scales adversely. Conclusion: Presence of comorbidity, low education levels, socioeconomic status and CT induced hematologic/gastrointestinal toxicities are the major parameters affect QOL in lung cancer. Chemotherapy leads to deterioration in social functions, increase in adverse events as well as worsening in economic status. Radiologic complete or partial response and small cell carcinoma are states in which parameters of QoL are affected positively by chemotherapy.

show abstract

“…4 In addition to their low OS rates, disease-related symptoms have a significant negative impact on patients' health-related quality of life (HRQoL). [5][6][7][8] Recent trials examining the clinical outcomes of treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death 1 ligand (PD-L1) as a monotherapy or in combination with chemotherapy have shown promising clinical results [9][10][11] and improvements in HRQoL in patients with nSQ-NSCLC. [12][13][14] Tislelizumab is a humanized monoclonal antibody against PD-1, 4,[15][16][17] which is under clinical development for the treatment of several solid tumor malignancies, including NSCLC.…”

mentioning

confidence: 99%

“…Platinum-based regimens are the standard first-line therapy for Chinese patients with locally advanced/metastatic nonsquamous (nSQ) non–small cell lung cancer (NSCLC) without epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) mutations 3 ; however, despite the available treatments, overall survival (OS) remains low for these patients 4 . In addition to their low OS rates, disease-related symptoms have a significant negative impact on patients' health-related quality of life (HRQoL) 5–8 . Recent trials examining the clinical outcomes of treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death 1 ligand (PD-L1) as a monotherapy or in combination with chemotherapy have shown promising clinical results 9–11 and improvements in HRQoL in patients with nSQ-NSCLC 12–14 …”

mentioning

confidence: 99%

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

Lü

Barnes³

et al. 2022

Cancer J

View full text Add to dashboard Cite

PurposeThis study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as first-line treatment on health-related quality of life (HRQoL) in patients with advanced nonsquamous non–small cell lung cancer (nSQ-NSCLC).MethodsPatients in this randomized, open-label, multicenter phase III study RATIONALE 304 (NCT03663205) with histologically confirmed stage IIIB/IV nSQ-NSCLC were randomized 2:1 to tislelizumab plus platinum-pemetrexed (arm T + PP) or platinum-pemetrexed alone (arm PP). Health-related QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Lung Cancer. Key patient-reported outcome endpoints include mean score change from baseline at weeks 12 (during chemotherapy) and 18 (following chemotherapy) in the 30-item Quality of Life Questionnaire Core's global health status/quality of life (GHS/QoL) and time to deterioration in GHS/QoL.ResultsThree hundred thirty-two patients received at least 1 dose of study drug and completed at least 1 HRQoL assessment. Global health status/QoL score improved in arm T + PP at week 18 (between-group least square mean difference, 5.7; 95% confidence interval [CI], 1.0–10.5; P = 0.018). Patients in arm T + PP experienced greater reduction in coughing (−5.9; 95% CI, −11.6 to −0.1; P = 0.044), dyspnea (−3.8; 95% CI, −7.8 to 0.1; P = 0.059), chest pain (−6.2; 95% CI, −10.8 to −1.6; P = 0.008), and peripheral neuropathy (−2.6; 95% CI, −5.5 to 0.2; P = 0.066). Median time to deterioration in GHS/QoL was not achieved for either arm.DiscussionThe addition of tislelizumab to platinum-based chemotherapy was associated with improvements in nSQ-NSCLC patients' HRQoL as well as the important disease-specific symptoms of coughing, chest pain, and dyspnea.ClinicalTrials.gov Identifier: NCT03663205

show abstract

Changes in and Determinants of Quality of Life in Patients With Advanced Non-Small-Cell Lung Cancer Undergoing Initial Chemotherapy

Cited by 18 publications

References 32 publications

Profiles of emotional distress and growth among adolescents and young adults with cancer: A longitudinal study.

Profiles of emotional distress and growth among adolescents and young adults with cancer: A longitudinal study.

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About